The first molecule believed to be a direct inhibitor of EWSR1–FLI1 is TK216, a YK-4-279 derivative, which recently entered phase II clinical trials in ES patients either as monotherapy or in combination with vincristine [112]. The gene discussed is EWSR1; the disease is Ewing sarcoma.